

The Adrenochrome Alternative

Harold D. Foster, Ph.D.¹

*But strange that I was not told
That the brain can hold
In a tiny ivory cell
God's heaven and hell.*

—Oscar Wilde 1854-1900

The Wrong Answer

“It may be said that a society shows itself just to the extent that it meets the needs of all its members and the quality of its civilization is determined by the way in which it protects its weakest members.”¹ If this is the case then we should be judged harshly. In most ‘civilized’ societies the mentally ill, mainly consisting of schizophrenics, are homeless, sleep in parks, under bridges or in dumpsters, beg muttering in the streets or, because of their irrational crimes, fill our prisons.

Schizophrenia may be the cruellest disorder² afflicting young adults, often beginning insidiously and progressing until the ambitions, potentials and hopes of early years are disregarded in disarray. In their place lie broken thoughts, inappropriate or stunted emotions and internal voices or other misperceptions that can make existence a living hell.² Unfortunately it is not rare. Schizophrenia is the commonest serious mental illness of the Developed World. In the USA it accounts for some 24 percent of all admissions to mental hospitals.³ Initially the disease is often episodic with acute phases interspaced with remissions but it often becomes chronic.

In his extremely interesting book *The Madness of Adam and Eve* Horrobin⁴ points out that:

“While in familial and personality terms the problem is devastating, in biochemical terms the problem cannot be very

serious. After all the young person functioned near normally for fifteen, twenty-five or thirty-five years before becoming ill. Moreover all schizophrenic patients vary in the severity of their illness often as documented earlier becoming near normal while the body temperature is elevated. The fundamental biochemical problem therefore cannot be too serious and must be reversible.”

This is an extremely intelligent and encouraging characterization. It seems fair to ask, however, if the problem is so biochemically simple why have countless thousands of doctors and scientists spent billions of dollars over more than 200 years in endless unsuccessful attempts to discover the etiology of schizophrenia?

The logical answer to this question must be that they are trying to hammer jigsaw puzzle pieces into spaces where they do not fit. Conventional drug treatment rests, to a large degree, on the ‘dopamine hypothesis’, that is on the belief that excess dopamine accentuates and decreased dopamine reduces the positive or hot symptoms of schizophrenia.⁵ The evidence for high levels of dopamine in schizophrenia is poor⁶ and Parkinsonism (the mimicking of Parkinson’s disease) has occurred frequently in patients treated for this hypothesized excess. Since Parkinson’s disease is known to stem from a dopamine deficiency it seems likely that drugs causing a similar illness in schizophrenics are creating a lack of this neurotransmitter rather than correcting an excess of it.

In the Genes

If too much dopamine is not the root cause of schizophrenia then what is? Certainly genetics must play a significant role because 50 percent of patients with this illness come from families

1. Department of Geography, University of Victoria, British Columbia, Canada hfoster@office.geog.uvic.ca

with a history of the disorder.⁷ This preponderance cannot be explained by abnormal child-rearing since adoption has no impact on the risk of subsequently becoming schizophrenic. There is beyond a doubt, therefore, a strong genetic component to schizophrenia but it cannot be as straightforward as the inheritance of certain characteristics such as eye colour since, as Myers⁸ points out, about half of the twins who share identical genes with a schizophrenic victim do not develop the disorder.² One must agree with Nicol and Gottesman's⁹ assessment that some individuals have a genetic predisposition to the disorder but that this predisposition by itself is not sufficient for the development of schizophrenia.² The schizophrenia genes therefore are not destiny but do enhance risk.

For many years geneticists have been studying groups of schizophrenics or individual families in which the disorder is unusually common in efforts to discover what if any genetic abnormalities they carry. To date four genetic aberrations¹⁰⁻¹³ have been identified that seem to occur more frequently than normal in subgroups of schizophrenics. These include the low enzyme activity variant of the catechol-O-methyltransferase gene, the GSTM1*O allele (required to produce a form of glutathione S-transferase) and possibly the C677TT variant of the gene for methylenetetrahydrofolate reductase. Beyond this many schizophrenics appear to have inherited an unusual Nogo (reticulin 4, RTN4, or RTN-X) variant gene from both parents. What these four genetic aberrations seem to have in common is that they all result in higher than normal exposure to adrenochrome, a metabolite of adrenaline, or in an abnormal susceptibility to its negative impacts. Since all of these variants are quite widely distributed in the human populace it seems likely that abnormal levels of adrenochrome carry evolutionary advantages. In sev-

eral publications including *What Really Causes Schizophrenia*^{2,14-16} I have argued that there appear to be not one but at least three and maybe four balanced genetic morphisms involved in this mental illness. The genetic aberrations increasing the risk of schizophrenia appear to promote religious sense technical and artistic creativity and leadership.¹⁷ They also seem to provide a greater resistance to a wide range of cancers especially that of the lung.¹⁸ While they may be extremely destructive in individuals prone to develop schizophrenia such genes are highly beneficial for humanity as a whole.

The Nature of Adrenochrome

In the early 1950s Osmond and Smythies realized that pink (that is deteriorated) adrenaline sprays were making some asthmatics psychotic causing them to hallucinate.¹⁹ Hoffer²⁰ knew that similar side effects accompanied the use of mescaline and made a list of all identified compounds that caused hallucinations in those who were awake. The list is short. It included harmline, mescaline, ibogaine, d-lysergic acid diethylamide (d-LSD-25, and deteriorated adrenaline. Hoffer was delighted to realize that all were indoles (LSD, harmline, ibogaine) or could become indoles (mescaline). It was not known what pink adrenaline was however until 1952 when Hutcheon²¹ described how the oxidation of adrenaline created the indole adrenochrome. Hoffer then experimented by taking this substance himself finding it made him paranoid. In another trial Osmond²² was administered 300mg of spray containing adrenochrome. Within 11 minutes his ears felt plugged and his vision became abnormal. Rapidly swinging one arm back and forward caused him to see it as a series of stationary arms. Within an hour he decided to cycle home from the hospital and noticed that the roadside trees were expanding as if being pumped up with air. Clearly he

was hallucinating. Arriving home earlier than usual he found his wife was out and became very depressed deciding that she must have left him and returned to her mother in a distant city. He counted all the suitcases. One was missing, increasing his certainty that she had gone. Finding a pile of clothes he concluded his wife had been packing to leave and had decided to go out to purchase her airline ticket. His depression increased. Remembering the experiment he became very angry with the person who had forced him to take adrenochrome. (He had in fact been a very willing participant in the experiment). Clearly he was becoming paranoid. This experimental evidence suggests that intelligent, highly educated individuals can be made to display many of the symptoms of acute schizophrenia very quickly simply by exposing them to excess adrenochrome. Put very simply, some people appear to become schizophrenic because their bodies manufacture an indole, adrenochrome, that has effects rather like a well-known psychedelic drug, LSD.

History of Schizophrenia

In a recently published book *The Invisible Plague: The Rise of Mental Illness from 1750 to the Present*, Torrey and Miller²³ argue that throughout human history the baseline rate of insanity was approximately one case for each 2,000 members of society. Using a great diversity of records ranging from mental health surveys to psychiatrists' diaries they are able to prove beyond reasonable doubt that industrialization has been accompanied by dramatic increases in mental illness. In England, Ireland, Canada, and the USA, for example, the prevalence of insanity as a rate per population increased at least sevenfold between the mid-18th and mid-20th centuries.² In the USA and especially in Ireland, the increase was greater. Torrey and Miller argue that we are now in the midst of an epidemic of

insanity so insidious that most people are even unaware of its existence.² The invisible plague appears worst in Ireland where the number of insane persons per 1,000 population has reached almost 8.0. This seems to be about 16 times the pre-industrial global baseline.

One does not have epidemics of genetic diseases simply because the human genome does not alter rapidly enough to cause them. The current epidemic of insanity associated with both schizophrenia and bipolar disorder that has developed over the past 250 years is a very strong argument that the triggers that increase the negative impacts of the genetic aberrations linked to this mental illness have become more common. These appear to include anything that either stimulates the body's production of adrenaline or promotes its metabolism to adrenochrome and its derivatives.

Pulling the Trigger

Stress

Stress is the easiest way to promote the metabolism of adrenaline in the human body. Although medical interest in stress can be traced back to Hippocrates²⁴ it was not until the 1920s that physiologist Walter Cannon²⁵ confirmed that response to stress is part of a unified mind-body system. Cannon was able to show that various stressors including extreme cold, lack of oxygen, and emotion-arousing incidents trigger an outpouring of epinephrine (adrenaline) and norepinephrine (noradrenaline). These enter the bloodstream from sympathetic nerve endings in the inner adrenal glands.²⁶ In those stressed, the sympathetic nervous system increases respiration and heart rate, diverts blood to skeletal muscles, and releases fat from storage. All these changes prepare the body for what Cannon called fight or flight and are obviously part of a response system that has evolved in an effort to deal with perceived threats.

Unfortunately, in situations of chronic stress, the fight or flight response becomes counterproductive, leading to a cumulative build up of adrenaline, noradrenaline, and cortisol. If these substances are not properly metabolized, long-term stress appears to promote disorders ranging from headaches and high blood pressure to rheumatoid arthritis and allergies.²⁷ What is significant here is that the fight or flight response to stress is associated with an elevation of adrenaline, oxidation of which can lead to an excess of adrenochrome. It is perhaps not surprising then that chronic stress is often linked to anxiety, poor concentration, depression, anger, frustration, fear, and sadness.²⁸ Of course if the individual being stressed carries one of the genetic aberrations linked to schizophrenia, adrenochrome levels are likely to be higher than normal and may be linked to the paranoia and hallucinations that this indole causes when taken accidentally or experimentally.²⁹ In summary, stress may be a trigger for schizophrenia because it increases the production of the precursors of adrenochrome.

Allergies

Physicians at the Moscow Psychiatric Institute used long fasts to treat schizophrenia, greatly improving the symptoms of 64 percent of all chronic patients who completed their program.³⁰ This strongly suggest that there may be dietary triggers for the disorder. Further support for this possibility comes from the recognition that such fasting normalizes catecholamine levels in the urine of schizophrenics.³¹

Countries where the national diet traditionally contains large quantities of cow's milk and wheat have poor recovery rates for schizophrenics.³² This is to be expected as some schizophrenics greatly improve on gluten free diets³³ perhaps because celiac disease is common in their families.³⁴ Indeed, Pfeiffer claimed that 10 percent of schizophrenics suffer from

a gluten allergy.³⁵ Hoffer also discovered that, in some fasting schizophrenics, the reintroduction of cow's milk caused hallucinations.³⁶ Indeed, 120 of Hoffer's 'problem patients', those who had not responded well to Orthomolecular treatment, experienced significant permanent improvements in their mental health after identifying and eliminating from their diets specific foods to which they were allergic.³⁷

These clues to the etiology of schizophrenia suggest that diet often plays a key role in triggering the disorder. This may be one of the reasons why so many recovered schizophrenics believe that they were formerly hypoglycemic and that they had greatly improved only after a major dietary change. How can so many different foods trigger one disease? The best way to understand a disorder is often to examine extreme cases. A few people are exceedingly allergic to a particular food, such as peanuts or salmon, or to a product such as latex, and can die rapidly if exposed to even small quantities of it.³⁸⁻³⁹ Allergic reactions can include skin rashes, itching, hives, burning eyes, swollen lips and tongue, difficulty breathing, wheezing, dizziness, abdominal pain, nausea and diarrhea. In rarer cases a strongly allergic individual suffers shock; blood pressure drops markedly the throat swells and airways in the lungs constrict. Without immediate treatment with epinephrine, death from anaphylactic shock occurs.

Interestingly the treatment of choice for anaphylaxis, whether caused by latex⁴⁰, peanuts, or insect stings⁴¹, is always epinephrine, a dilute solution of adrenaline. This is because during an allergic reaction the chronic inflammatory response is usually characterized by numerous polymorphonuclear leukocytes⁴², the presence of which have been shown by Matthews and co-workers⁴³ to be linked to the oxidation of adrenaline to adrenochrome. In such an allergic reaction oxidation of

adrenaline to adrenochrome is detectable within 5 minutes and continues for at least 4 hours.

Of course, many people are allergic to substances that occur in water supplies or as air pollutants or as an integral part of products of one type or another.⁴⁴ This may be one of the reasons why schizophrenia's prevalence has markedly increased during the Industrial Revolution. Industrialization has brought with it an enormous range of pollutants that adversely affected air water and soil quality. By 1977, the American Chemical Society had registered some four million chemical compounds, 32,000 of which were in commercial use.⁴⁵ It is unknown how many of these are potentially dangerous, although there are currently some 2,450 substances that are thought to cause cancer in the workplace. While attempts are generally made to establish the possible carcinogenicity of such industrial chemicals, their potential effects on mental health rarely appear to be considered.

Hypoglycemia

Hypoglycemia was initially described by Dr. Seale Harris⁴⁶ in 1924 when he discovered that sugar consumption stimulated the body to release insulin which, in turn, drove blood sugar levels down. Harris discovered that a high-protein, low-sugar diet eaten at frequent small meals maintained a normal and stable blood sugar level so controlling hypoglycemia. Since the United States sugar consumption⁴⁷ per capita has increased by roughly a factor of 20 since 1822, hypoglycemia has become rampant in its population.⁴⁸

Many recovered schizophrenics feel that they had previously suffered from hypoglycemia. Schauss⁴⁹ also estimated that between 80 and 85 percent of criminals in US prisons suffer from hypoglycemia, often eating an excess of sugary foods and repeatedly drinking sugar-sweetened coffee and/or Kool-Aid. It is well known that

when blood sugar levels drop, adrenaline is released from the adrenal glands because it is involved in the metabolism of glucose.⁵⁰⁻⁵¹ It follows, therefore, that anyone suffering from the large blood sugar swings characteristic of hypoglycemia (associated with a diet that is too rich in sugar) is going to overproduce adrenaline. Hypoglycemic individuals with one or more of the genetic aberrations seen in schizophrenia are therefore likely to suffer psychosis caused by adrenochrome created by the oxidation of this excess adrenaline.

Biochemical and Clinical Impacts of Adrenochrome

Besides being an hallucinogen, adrenochrome is a highly reactive neurotoxin that in schizophrenia undermines at least three major biochemical systems.⁵² It is an antagonist of the hormone triiodothyronine and can and often does seriously damage the thyroid. In chronic schizophrenics, this gland impairment appears permanent. Adrenochrome also has a Jekyll and Hyde relationship with serotonin and, so, impacts on tryptophan and its other chief metabolite, niacin. At low levels, serotonin appears to stimulate adrenochrome formation while at higher levels it retards the process.

Adrenochrome also generates numerous free radicals causing oxidative stress, eventually exhausting the schizophrenic antioxidant defence systems, creating deficiencies of glutathione peroxidase, superoxide dismutase and catalase. Complicating the impacts of high adrenochrome conversion from adrenaline are the numerous interactions that normally occur between triiodothyronine, serotonin, and the three major components of the antioxidant defence system. In chronic schizophrenics, who have suffered for years, these biochemical abnormalities result in brain atrophy associated with large fluid filled spaces known as ventricles and

seriously damaged thyroid glands.

Treatment and Prevention: Eight Steps

If the adrenochrome hypothesis is correct, the ideal treatment for schizophrenia should involve eight steps designed to reduce the production of adrenaline and slow down its metabolism to adrenochrome and other toxic indoles. Such a treatment should also attempt to reduce the further biochemical abnormalities that result from either an excess of adrenochrome and its metabolites or from other impacts of the four genetic aberrations that appear associated with this mental illness.

Since many schizophrenics are over-oxidizing adrenaline because of allergic reactions, they need extra-special surroundings because of such sensitivities. Ideally a treatment clinic would be like the Lange Meridian Centre⁵³ which was built using Bau-Biologie principles. Step two involves genetic and biochemical screening to identify the most likely effective treatment protocol. Allergy testing is also essential as is a low sugar diet.⁵⁴ The fifth step in the treatment of schizophrenia should involve medications that must quickly reduce the destructive impacts of excess adrenochrome and its derivatives. They must also address the other biochemical anomalies directly related not to such indoles but to the genetic aberration encouraging their overproduction. In schizophrenics with the MTHFR C677TT variant, for example, the patient will also be suffering from depressed methionine and elevated homocysteine.

There appear to be several avenues for lowering excess adrenochrome levels.⁵⁵ These include high doses of niacin or niacinamide and the use of other natural methyl acceptors thiamine (vitamin B₁), riboflavin (vitamin B₂), and ubiquinone (Coenzyme Q₁₀). Niacin is usually the treatment of choice.

Another adrenochrome antagonist,

triiodothyronine, appears very effective in treating schizophrenia. As shown by Danziger⁵⁶, every one of the 80 schizophrenics who had been ill for 6 months or less who took between 120 to 1,200 milligrams of desiccated thyroid daily for at least 100 days recovered, suffering relapses only if they later discontinued their medication. These doses may seem high but it should be remembered that schizophrenics are known to be very resistant to thyroid medications. This is probably because all chronic schizophrenics appear to be suffering from badly damaged thyroid glands.

Treatment might also involve attempts to directly raise body levels of another adrenochrome antagonist, serotonin. If serotonin is not provided as a supplement, its metabolism could be encouraged by the consumption of foods that are high in tryptophan such as beans, cod, pork, and cheese (provided that the patient is not allergic to them). In addition, every effort should be made to repair the antioxidant defence system, increasing glutathione peroxidase, catalase and superoxide dismutase activity.

Since there appear to be several genetic aberrations involved in schizophrenia, subgroups of patients also will suffer from distinct biochemical imbalances that need correction. The sixth step of the treatment protocol should address these. To illustrate, schizophrenics with the MTHFR C677TT variant of the gene encoding for methylenetetrahydrofolate will suffer from an excess of homocysteine and a deficiency of methionine, even if treatment reduces adrenochrome levels. Beyond the provision of methionine, since the remethylation (or detoxification) of homocysteine requires folic acid, vitamin B₁₂, zinc and trimethylglycine, it is likely that schizophrenics with this genetic aberration will require high doses of these nutrients.

Adrenochrome excess and the other

biochemical abnormalities that occur in schizophrenia can eventually cause serious damage to the thyroid gland⁵⁷ as well as to the brain itself. Long term chronic patients are therefore much more difficult to treat successfully. This task might not be impossible but it will almost surely require higher doses of Orthomolecular nutrients taken for longer periods before improvement is apparent.

One of the major problems in chronic schizophrenia is the development of brain atrophy associated with large fluid-filled spaces known as ventricles. Buckman and co-workers⁵⁸ provided evidence that blood levels of the selenoenzyme, glutathione peroxidase, have a strong negative correlation with computer tomography scan measures of such brain damage. Simply put, the less blood glutathione peroxidase the greater the brain damage in chronic schizophrenics. Obviously, one treatment strategy worth trying is supplementation with the four nutrients, selenium, cysteine, glutamine, and tryptophan, that the body requires to produce glutathione peroxidase.⁵⁹ Injected glutathione may be of value. There is also growing evidence that eicosapentaenoic acid can repair ventricle damage in chronic schizophrenics leading to an improvement in their mental health.⁶⁰⁻⁶²

It is clear that damage is not restricted to the brain in chronic schizophrenics. All of these patients also appear to suffer from extensive thyroid abnormalities.⁶³ I do not know how to repair a damaged thyroid gland. If this is impossible, significant behavioural improvements can only be expected when using a protocol that includes continuous desiccated thyroid gland supplementation.

The eighth and final step in the treatment of schizophrenia involves treatment for the soul. Recovering schizophrenics are still one of the few groups society feels free to abuse, ostracize, and discriminate against. While it is socially acceptable to

admit to having cancer, heart disease, multiple sclerosis or Parkinson's disease, admitting to schizophrenia invites fear and derision. To recover, schizophrenics need employment, respect and compassion. Too often they receive rejection abuse and insult.

References

1. Letter of John Paul II to the President of the Second World Assembly on Ageing (Madrid 8-12 April 2002. http://www.vatican.va/holy_father/john_paul_ii/letters/2002/documents/hf_jp-ii_let_20020410_assembly-ageing_en.html
2. Torrey EF: *Schizophrenia and Civilisation*. 1980. New York: Jason Aronson.
3. Fishbein 1985. Fishbein's Illustrated Medical and Health Encyclopaedia. Westport CT: Stuttmann.
4. Horrobin D: *The Madness of Adam and Eve*. 2002. London: Transworld Publishers.
5. Seeman P Guan HC Van Tol HH: Schizophrenia: Elevation of dopamine D4-like sites using [3H] nemonapride and [125I] epidepride. *Eur J Pharmacol*. 1995; 2862: R3-5.
6. Issa F Gerhardt GA Bartko JJ et al: A multidimensional approach to analysis of cerebrospinal fluid biogenic amines in schizophrenia: I. Comparisons with healthy control subjects and neuroleptic-treated/unmedicated pairs analysis. *Psychiat Res* 1994; 52/3: 237-249.
7. Myers DG: *Psychology*. 1992. New York: Worth Publishers.
8. Ibid.
9. Nicol SE Gottesman II: Clues to the genetics and neurobiology of schizophrenia. *Am Scientist* 1983 : 71: 398-404.
10. Park TW Yoon KSKim JH et al: Functional catechol-O-methyltransferase gene polymorphism a susceptibility to schizophrenics. *Euro Neuropsychopharmacol* 2002; 12/4: 299-303.
11. Harada S Tachikawa H Kawanishi Y: Glutathione S-transferase M1 gene deletion may be associated with susceptibility to certain forms of schizophrenia. *Biochem Biophys Res Comm* 2001; 281: 267-271.
12. Deng H Liu X Cai G Sun X et al: A linkage disequilibrium study of methylenetetrahydrofolate reductase C677T and schizophrenia. *Zhonghua Yi Xue Yi Chuan Xue Za Zhi* 2002; 19/3: 198-200.
13. Novak G Kim D Seeman P, Tallerico T: Schizophrenia and Nogo: Elevated mRNA in cortex and high prevalence of a homozygous CAA

- insert. *Molecular Brain Research*, 2002; 1072: 183-189.
14. Foster HD: What Really Causes Schizophrenia 2003. Victoria BC: Trafford Publishing.
15. Hoffer A, Foster HD: Why schizophrenics smoke but have a low incidence of lung cancer: Implications for the treatment of both disorders *J Orthomol Med*, 2000; 15/3: 141-144.
16. Foster HD, Hoffer A: Schizophrenia and cancer: The adrenochrome balanced morphism. *Med Hypoth* 2004;62/3:415-419.
17. Horrobin op.cit.
18. Hoffer and Foster op.cit.
19. Hoffer A: *Orthomolecular Treatment For Schizophrenia: Megavitamin Supplements of Nutritional Strategies for Healing and Recovery*. 1999. Los Angeles: Keats Publishing.
20. Ibid.
21. Ibid.
22. Dishinger RC 1998. *Bad Behaviour and Illness are Caused by Biochemical Imbalances*. Owensboro KT: 1998. Medici Music Press.
23. Torrey EF, Miller J: *The invisible Plague: The Rise of Mental Illness From 1750 to the Present*. 2002. New Brunswick NJ: Rutgers University Press.
24. Myers op. cit.
25. Ibid.
26. Ibid.
27. Mind/Body Education Center. The Fight or flight Response. <http://www.mindbodymed.com/EducationCenter/fight.html>
28. Ibid.
29. Dishinger RC op.cit.
30. Cott A: Controlled fasting treatment of schizophrenia. *Schizophrenia*, 1971; 3: 2-10.
31. Ibid.
32. Templer D, Veleber DM: Schizophrenia prevalence: Wheat milk and temperature. *J Orthomol Psychiat*, 1980; 9/4: 284-286.
33. Vissodes DN, Venulet A, Jenner FA: A double-blind gluten-free/gluten-load controlled trial in a secure ward population. *Brit J Psychiat*, 1986; 148, 447-452.
34. Dohan FC: Hypothesis: Genes and neuroactive peptides from food as cause of schizophrenia. In Costa and M Trabucchi (Eds.), *Neural Peptides and Neural Communication*. 1980. New York: Raven Press. p. 535-538.
35. Pfeiffer CC: *Nutrition and Mental Illness: An Orthomol Approach to Balancing Body Chemistry*. 1987. Rochester VT: Healing Art Press.
36. Kail K, Lawrence B, Goldberg B: *Allergy Free: An Alternative Medicine Definitive Guide*. 2000. Tiburon CA: Alternative MedicinEcoM
37. Ibid.
38. Ibid.
39. American Academy of Allergy Asthma and Immunology. Fast facts: Statistics on asthma and allergic diseases. 1999. www.aaaaa.org.
40. Valeri CR, Altschule MD, Pivace LE: The hemolytic action of adrenochrome and epinephrine metabolite. *J Med*, 1972; 31, 20-40.
41. Baumgartner A Wokalek H; Schöpf E: Bee and wasp venom allergy. *Fortschr Med*. 1989; 10721, 460-463.
42. Nasjleti CE, Caffesse RG, Kowalski CJ: Dextran-induced inflammation and its effect on keratinized gingival epithelium in monkeys. *J Periodontology*, 1984; 55/9: 531-535.
43. Matthews SB, Hallet MB, Henderson AH, Campbell AK: The adrenochrome pathway. A potential catabolic route for adrenaline metabolism in inflammatory disease. *Adv Myocardiol*, 1985; 6: 367-381.
44. Foster HD: Schizophrenia: The latex allergy hypothesis. *J Orthomol Med*, 1999; 142, 83-90.
45. US Environmental Protection Agency. *Toxic Substances Control Act (TSCA), PL-94-469: Candidate List of Chemical Substances 1-3* Washington DC Environmental Protection Agency Office of Toxic Substances. 1977.
46. Schauss A: *Diet Crime and Delinquency* 1980. Berkeley CA: Parker House.
47. Ibid. citing data from the *National Food Situation* 138 1971.
48. Phelps JK, Nourse AE: 1986. *The Hidden Addiction and How to Get Free*. Boston MS: Little Brown and Company.
49. Schauss op. cit.
50. Watt MJ, Hargreaves M: Effect of epinephrine on glucose disposal during exercise in humans: Role of muscle glycogen. *Am J Physiol Endocrinol Metab*, 2002; 283/3: E578-583.
51. Vicini P, Avogaro A, Spilker ME et al: Epinephrine effects on insulin-glucose dynamics: The labelled IVGTT (Intavenous Glucose Tolerance Test) two-compartment minimal model approach *Am J Physiol Endocrinol Metab*, 2002; 283/1: E78-84.
52. Foster 2003 op.cit.
53. Baubiologic Home Study Course. <http://www.bau-biologieusa.com.def.html>
54. Schauss A op. cit.
55. Hoffer op. cit.
56. Danziger cited by Hoffer A: Thyroid and schizophrenia. *J Orthomol Med*, 2001; 16/4: 205-212.
57. Skoliarova NA: Morphology of the endocrine system in schizophrenia according to early autopsy findings (the Hypophyseal-Thyroid

- System). *Zhurnal Nevropatologii Psikiatrii Imeni SS Korsakova* 1975; 75/7: 1045-1053 (in Russian abstract only consulted).
58. Buckman TD, Kling A, Sutphin MS et al: Platelet glutathione peroxidase and monoamine oxidase activity in schizophrenics with CT Scan abnormalities: Relation to psychosocial variables. *Psychiat Res*, 1990; 311: 1-14.
59. Mariorino M, Aumann KD, Brigelius-Flohe R, et al. Probing the presumed catalytic triad of a selenium-containing peroxidase by mutational analysis. *Z Ernährungswiss*, 1998; 37 (Supplement 1): 118-121.
60. Emsley R, Myburgh C, Oosthuizen P et al: 2002. Randomized placebo-controlled study of ethyl-eicosapentaenoic acid as a supplement treatment in schizophrenia. *Am J Psychiat*, 2002; 115/9: 1596-1598.
61. Horrobin DF, Jenkins K, Bennett CN, Christie WW: Eicosapentaenoic acid and arachidonic acid: Collaboration and not antagonism is the key to biological understanding. Prostaglandins *Leukot Essent Fatty Acids* 2002; 66:1: 83-90.
62. Peet M, Brind J, Ramchand CN: Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. *Schizophrenia Research*, 2001; 49/3: 243-251.
63. Skoliarova op.cit.